Company: CSTL
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001447362-25-000097
Chunk: 2

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-08-04
Form: 10-Q
Item: Item 1
Chunk 2
---
uted29,545 28,738 28,763 28,542 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.2

Table of Contents

CASTLE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(in thousands)

Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Net income (loss)$4,523 $8,920 $(21,325)$6,386 Other comprehensive loss:Net unrealized loss on marketable investment securities(92)(61)(191)(308)Comprehensive income (loss)$4,431 $8,859 $(21,516)$6,078 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.3

Table of ContentsCASTLE BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(UNAUDITED)(in thousands, except share data)

Common StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOther Comprehensive Income (Loss) TotalStockholders’EquitySharesAmountBALANCE, JANUARY 1, 202427,410,532 $27 $609,477 $(218,371)$136 $391,269 Stock-based compensation expense— — 12,675 — — 12,675 Exercise of common stock options19,066 — 65 — — 65 Issuance of common stock from vested restricted stock units and payment of employees’ taxes44,830 — (474)— — (474)Issuance of common stock under the employee stock purchase plan111,241 1 1,707 — — 1,708 Net unrealized loss on marketable investment securities— — — — (247)(247)Net loss— — — (2,534)— (2,534)BALANCE, MARCH 31, 202427,585,669 $28 $623,450 $(220,905)$(111)$402,462 Stock-based compensation expense— — 13,179 — — 13,179 Exercise of common stock options1,779 — 8 — — 8 Issuance of common